Print ISSN:-2249-8176

Online ISSN:-2348-7682

CODEN : PJMSD7

Current Issue

Year 2024

Volume: 14 , Issue: 2

  • Article highlights
  • Article tables
  • Article images

Article Access statistics

Viewed: 208

Emailed: 0

PDF Downloaded: 2412


Rizvi, Waris, Ali, Faizi, and Ahuja: Retinopathy of prematurity: Risk factors and associated co-morbidities


Introduction

Retinopathy of prematurity (ROP) is a disorder of developing retinal vasculature mainly characterised by abnormal development of retinal vessels and is an important preventable cause of childhood blindness. The mechanism for ROP development is vasoconstriction and obliteration of the advancing capillary bed resulting in retinal oedema, retinal haemorrhage, extraretinal fibrovascular proliferation, traction, and eventually, detachment of the retina leading to blindness.1 Theodore L. Terry, in 1942, first used the term "Retrolental Fibroplasia" for this suspecting prematurity as a predisposing factor for the disease. Further, Kinsey et al.,2 in 1956, found that "the length of time premature babies are kept in an oxygen-enriched environment is an important factor in the development of retrolental fibroplasia. The aetiology of ROP is multifactorial, with three factors having a consistent and significant association with ROP: low gestational age LGA low birth weight LBW and prolonged exposure to supplementary oxygen following birth.

The World Health Organization identifies ROP as an important cause of preventable blindness in its Vision 2020 program, especially in middle-income countries,3 and considers the control of childhood blindness a top priority for three main reasons. Firstly, the number of "blind years" is particularly high for a person blinded in infancy. Secondly, many causes of childhood blindness, including ROP are ether preventable or treatable. Hence they can be controlled if diagnosed and treated on time. Thirdly, many causes of childhood blindness are associated with increased child mortality (e.g. premature birth, congenital rubella syndrome, measles, meningitis and vitamin A deficiency). Thus, control of blindness in children is also closely linked to child survival.3

ROP is responsible for 0-16.9% of children's severe visual impairment/blindness in Asian countries. 4 It is emerging as one of the leading causes of preventable childhood blindness in India. 5 India accounts for the most preterm births in the world (3.5 million) 6 and has the third-highest incidence of L.B.W. being delivered every year, with about 1.7 million weighing <2500 g and about 0.4 million <1500 gm. 7 Crucially, premature birth and L.B.W. predispose a newborn to develop ROP, for which India is the hotbed.

However, subtle differences in the quality of neonatal care, genetic composition, infant mortality rate and incidence of premature birth limit their applicability and extrapolation in developing countries such as India. There is a need to find the prevalence and risk factors associated with ROP to understand the extent of the problem in our country for appropriate intervention to combat this disease. There is a paucity of studies in the northern parts of India, especially in Uttar Pradesh, the most populous state of the country with a population of 199,812,341 (16.51 % of India's population).

Therefore, this study was conducted to look for the prevalence and predisposing risk factors of ROP. We also tried to find out co-morbidities associated with ROP and study its pattern among preterm babies admitted to the NICU of our centre.

Materials and Methods

The study population was drawn from the NICU of Jawaharlal Nehru Medical College and hospital A.M.U., Aligarh. The study population included all the neonates with a gestational age of less than 36 weeks admitted to the NICU of our college from January 2018 to June 2019. Informed written consent was taken from each patient's guardian before participation in the study. Neonates whose guardians did not give consent, babies with hazy ocular media, and those who died before fundus examination were excluded from the study.

Anterior segment examination was done using a torchlight/direct ophthalmoscope to look for conjunctiva, cornea, lens/ media clarity, and the pupillary reaction. The pupil was dilated with mydriatic eye drop containing (tropicamide 0.4%, phenylephrine 2.5% and Cyclopentolate 0.5%), instilled every 15 minutes for 3-4 times, starting 1 hour before the posterior segment examination. The retinal examination was done using an indirect binocular ophthalmoscope and 28 dioptre lens, using Alfonso eye speculum and Schocket scleral depressor. Findings were drawn on a retinal diagram mentioning the zone, stage, the extent of disease in clock hours, and the presence of pre-plus or plus disease.

ROP staging was done as per ICROP classification, and further treatment was done according to guidelines laid by the ETROP study. Patients with non-vascularised peripheral temporal retina at 36 weeks were reviewed in retina clinic/NICU at a two-week interval until ROP requiring treatment developed or vascularisation of the retina reached the expected completion. Patients were treated using laser and intravitreal anti-VEGF injections as per the need. Their ocular condition was recorded, and follow-ups were scheduled for. The study was approved by the multidisciplinary research ethics and advisory committee, J.N. Medical College and hospital, A.M.U.

Statistical analysis

The data were entered and analysed using IBM SPSS® Version 20. The prevalence of ROP was described in percentage proportion. Chi-square test and Fisher exact test were used to analyse categorical variables, as applicable. For continuous variables, independent sample t-test and Mann-Whitney U test were used as appropriate. A p-value of < 0.05 was taken as statistically significant. Further, multivariate analysis was done to adjust for factors that were found significant in univariate analysis.

Results

The study population included 164 babies with a gestation age < 36 weeks. 87 (53.05%) were male, and 77 (46.95%) were female. The mean gestational age of babies enrolled was 32.43±2.18 weeks (26 weeks to 35.71 weeks). The mean birth weight was 1.55 kg±0.39 kg (range: 0.86 kg-2.76 kg). 92 (56.10%) babies were delivered normally, and 72 (43.90%) were delivered by caesarean section. Among 164 babies, 126 (76.83%) were born singleton, 33 (20.12%) were twins, and 5 (3.05%) were born as triplets.

Table 1

Demographic data of the respondents

Data

n (%) or mean±SD

Sex

Male

87 (53.05%)

Female

77 (46.95%)

Mean Gestational Age

32.43±2.18 weeks

Mean Birth Weight (g)

1.55±0.39 kg

Mode of Delivery

Normal delivery

92 (56.10%)

Caesarean section

72 (43.90%)

Type of Gestational

Singleton

126 (76.83%)

Twins

33 (20.12%)

Triplet

5 (3.05%)

Table 2

Risk factors associated with ROP

Cases with ROP (n=29)

Cases without ROP (n=135)

p-value

Sex

Male (87)

17 (19.54%)

70 (80.46%)

0.508

Female (77)

12 (15.58%)

65 (84.42%)

Gesatational age (weeks)*

<28 weeks

3 (42.86%)

4 (57.14%)

<0.001

28-32 weeks

15 (24.59%)

46 (75.41%)

>32 weeks

11 (11.46%)

85 (88.54%)

Birth weight (kg)*

<1.00 kg

6 (50%)

6 (50%)

<0.001

1.00-1.49 kg

18 (23.68%)

58 (76.32%)

1.50-2.49 kg

5 (6.58%)

71 (93.42 %)

Multiple gestation*

Singleton

18 (14.28 %)

108 (85.72%)

0.004

Twins

7 (21.21%)

26 (78.79%)

Triplets

4 (80%)

1 (20%)

Mechanical ventilation* (n=12)

5 (41.67%)

7 (58.33%)

0.039

History of oxygen therapy* (n=55)

23 (41.82%)

32 (58.18%)

<0.001

Duration of oxygen therapy* (days)

6.45±5.62

0.88±2.37

<0.001

History of blood transfusion* (n=9)

5 (55.56%)

4 (44.44%)

0.009

Apgar score 1 min

5.97 ± 1.52

6.30 ± 1.17

0.193

Apgar score 5 min

7.55 ± 0.74

7.84 ± 0.81

0.075

Respiratory distress syndrome* (n=42)

16 (38.10%)

26 (61.90%)

<0.001

Neonatal jaundice (n=61)

8 (13.11%)

53 (86.89%)

0.238

Apnea* (n=11)

8 (72.73%)

3 (27.27%)

<0.001

Sepsis* (n=44)

13 (29.55%)

31 (70.45%)

0.016

Shock (n=5)

2 (40%)

3 (60%)

0.214

Hypocalcaemia (n=6)

2 (33.33%)

4 (66.67%)

0.287

Necrotising enterocolitis (n=8)

2 (25%)

6 (75%)

0.632

Thrombocytopenia (n=4)

2 (50%)

2 (50%)

0.144

[i] * Statistically significant

Table 3

Risk factors for ROP; Multivariate logistic regression analysis

OR

95% C.I. for OR

p-value

Gestational age

.923

.707

1.206

0.558

Supplemental oxygen therapy*

5.530

1.609

19.005

0.007

Apnea*

7.139

1.144

44.565

0.035

RDS*

6.745

2.047

22.224

0.002

Birth weight*

.076

.009

.664

0.020

Multiple gestation

2.384

.696

8.170

0.167

Mechanical ventilation

1.498

.275

8.146

0.640

Blood transfusion

1.817

.199

16.578

0.597

Sepsis

.525

.148

1.864

0.319

[i] * Statistically significant

Table 4

Association between oxygen supplementation and stages of ROP

Stage of ROP

Cases required oxygen therapy

Cases without oxygen therapy

p-value

Stage 1 (n=15)

10

5

<0.001

Stage 2 (n=9)

8

1

Stage 3 (n=3)

3

0

Prevalence of ROP

The prevalence of ROP was 17.68% (29/164). Among those suffering from ROP, 29 babies 51.72% (15/29) had stage 1, 31.03% (9/29) had stage 2, 10.35 % (3/29) had stage 3 and 6.90% (2/29) babies had APROP. None of the babies progressed to stage 4 or 5. The disease was localised to zone 1 in two cases (6.9%), zone 2 in eight cases (27.59%), and in nineteen cases (65.51%) the disease was confined to zone 3.

Table 2 depicts the association between ROP and various risk factors and co-morbidities. A significant association was observed between ROP occurrence and gestational age, low birth weight, multiple gestation, mechanical ventilation, history and duration of oxygen supplementation, history of blood transfusion, respiratory distress syndrome, apnea, and sepsis. However, an insignificant association was found between ROP and sex, mode of delivery, Apgar score at 1 and 5 minutes, neonatal jaundice, shock, hypocalcaemia, necrotising enterocolitis, thrombocytopenia (all p > 0.05).

Factors that were statistically significant after univariate analysis were further analysed for multivariate analysis using multiple logistic regression. Birth weight, supplemental oxygen therapy, apnea and R.D.S. were significant even after multivariate analysis (Table 3). Further, a statistically significant association was found between oxygen supplementation and stages of ROP, as shown in Table 4.

Discussion

This study was conducted by the Institute of Ophthalmology in collaboration with NICU, Department of Paediatrics, J.N.Medical College, A.M.U, Aligarh, to find the prevalence of ROP and associated co-morbidities in preterm babies admitted to NICU of our Hospital.

The prevalence of ROP was found to be 17.68% (29/164). The prevalence of ROP in India is relatively high and ranges from 2.3%% to 47.2%.8, 9, 10, 11, 12, 13, 14 Le et al. (Telangana, 2016) reported a prevalence of 2.3% (66/2910), 14 Parekh et al. (Maharashtra, 2016) 28.57% (44/154), 15 Ashwani Kumar et al. (Punjab, 2017) reported a prevalence of 40% (31/77), 11 while Mantri et al. (Rajasthan, 2017) reported a prevalence of 13.6 % (34/250). 13 This vast disparity is attributed to the fact that neonatal care is highly variable in different parts of our country.

Risk factors associated with ROP

We found prematurity to be significantly associated with ROP, which has been proven in many other studies.14, 16, 17, 18, 19, 20, 21, 22 It was observed that 42.86% (3/7) of extremely preterm babies developed ROP, 24.59% (15/61) of very preterm babies developed ROP and among remaining moderate to late preterm babies, only 11.46% (11/96) babies developed ROP A significant association was observed between prematurity and development of ROP after univariate analysis. This inferred that babies born at lower gestational age are more prone to develop ROP. The probable reason behind this association is incomplete vascularisation of the retina as vascularisation completes in 38-40 weeks of gestation. The immature retina is more susceptible to insults that disrupt vascular growth and leads to ROP. 23, 24 Such an immature retina is also more likely to get oxidative damage hyperoxia or hypoxia, blood transfusions, and sepsis, which are known factors contributing to ROP development. In the CRYO-ROP cohort, it was observed that each additional week of gestational age decreases the odds of reaching threshold disease by 19%. 25 However, in multivariate analysis, no significant association was found between low gestational age and ROP occurrence. This may be because most preterm babies who did not have any other associated co-morbidities did not develop ROP. Similar findings were observed after multivariate analysis in many other studies conducted across the globe, indicating that gestational age does not independently determine the development of ROP 18, 26, 27

Low birth weight was another significant risk factor for the development of ROP. Low birth weight was another significant risk factor for the development of ROP. Among extremely low birth weight babies(1.00 kg) 50% (6/12) babies developed ROP, 23.76%(18/76) babies with very low birth weight (1 to 1.49kg) developed ROP and among the remaining Low birth babies(1.5 to 2.49 kg) only 6.58% (5/76) developed ROP. Similar results were observed in the multicenter trial of cryotherapy (CRYO ROP study), where it was concluded that lower the birth weight, greater the risk of developing ROP, especially in infants with birth weight less than 750 gm. It was also reported that for every 100 gm increase in birth weight, there is a 27% decrease in odds of reaching threshold ROP. 25 Our results were also supported by observations of many other studies which reported a significant relationship between ROP and birth weight. 19, 28, 29, 30, 31, 32, 33 This association can be explained by the fact that low birth weight is associated with prematurity and many other co-morbidities which have a direct association with ROP

This study also revealed a significant relationship between oxygen supplementation and ROP development (p-value<0.001). Our findings were also supported by many other studies conducted in India 10, 13, 14 and across the world. 17, 22, 34, 35 This association can be explained by the fact that inside the uterus baby is in a hypoxic state after delivery, supplemental oxygen induces hyperoxia and suppresses normally produced growth factors (VEGF) which result in cessation of growth of retinal vasculature. Subsequently, the increasing metabolically active but poorly vascularised retina becomes ischemic. It leads to a surge of VEGF, further leading to the sudden proliferation of vessels and the development of ROP 36 On the other hand, in a study conducted by Palmer et al. (2005) and Alizadeh et al. (Iran, 2015), no significant association was found between ROP and supplemental oxygen. They also stated that ROP might develop in cases that did not have any history of oxygen supplementation. 37, 38

A significant association was observed between duration of oxygen supplementation on ROP development. This result was also supported by Norman Ashton et al., who, in their randomised controlled trial in 1956, reported that the severity of the vaso-obliterative effect of oxygen is directly proportional to the concentration and duration of oxygen administered. 39

However, no significant relationship was observed between ROP and multiple gestations, mechanical ventilation, blood transfusion, Apgar score at 1 and 5 minutes, neonatal jaundice.

Co-morbidities associated with ROP

Many co-morbidities are linked with ROP. By reducing these morbidities or managing them properly, we can reduce the incidence of this disease.40

In our study, we observed a significant association between R.D.S. and ROP (p-value <0.001). Similar results have been reported by other previous studies. These results are unsurprising because R.D.S. requires supplemental oxygen, which induces hyperoxemia in the developing retina, thus arresting the retinal vascular growth. Consequently, the resulting hypoxia of the retina causes ROP 41. However, Alajbegovic et al. (Europe, 2015) and Hakeem et al. (Egypt, 2012) reported an insignificant association between ROP and R.D.S. 20, 42

A ‎statistically significant association between ROP and apnea (p-value<0.001) was also observed in this study.‎ Similar findings were reported by Alizadeh et al. 43 Chattopadhyay et al. Le et al Kumar et al. Wu et al. Fluctuation of arterial ‎oxygen tension (PaO2) occurs during apneic attacks, which has a more adverse effect on proliferative retinal diseases ‎than hyperoxia alone, leading to neovascularisation and ‎development of ROP 44, 43

Many other co-morbidities like neonatal jaundice, shock, hypocalcaemia, necrotising enterocolitis, sepsis and thrombocytopenia were also considered in this study. None of them showed any statistically significant association with the development of ROPs.

Almost all babies with stage 1 and stage 2 disease underwent spontaneous regression except for four babies, whose fate is unknown, as they were lost to follow up, whereas babies with stage 3 and APROP disease were treated with laser/ Anti- VEGF.

Conclusion

In a nutshell, a prevalence of 17.68% in this study from a tertiary centre in western Uttar Pradesh emphasises the importance of neonatal screening in this region. Low birth weight, oxygen therapy, apnea, respiratory distress syndrome pose a significant risk factor for ROP. Timely ROP screening of high-risk preterm babies is essential to prevent the development of advanced ROP None of the babies in our study developed stage 4 or 5 ROP, emphasising the importance of timely ROP screening in reducing the severity of the disease. Since ROP may produce serious sequelae leading to complete blindness, no stone should be left unturned to prevent the development of advanced ROP by reducing preterm births, improving neonatal care, proper monitoring of oxygen saturation. We should wean off supplemental oxygen as early as possible since it is detrimental to the occurrence and severity of ROP. An adequate number of trained retinal surgeons in ROP care is required as the magnitude of the problem is ever-increasing. Government programs are required in this field to make the patients aware regarding the complications of this disease and to emphasise on the importance of screening for close follow up of such neonates.

Conflict of Interest

The authors declare that they have no conflict of interest.

Source of Funding

The authors received no funding for this work.

References

1 

V Kulkarni V Kulkarni P Jonnala Incidence and Risk Factors of Retinopathy of Prematurity: A Retrospective Observational StudyPerinatology2017181315

2 

V E Kinsey J T Jacobus F M Hemphill Retrolental fibroplasia; cooperative study of retrolental fibroplasia and the use of oxygenAMA Arch Ophthalmol195656448154310.1001/archopht.1956.00930040489001

3 

C Gilbert A Foster Childhood blindness in the context of VISION 2020--the right to sightBull World Health Organ200179322732

4 

C Gilbert J Rahi M Eckstein J O'Sullivan A Foster Retinopathy of prematurity in middle-income countriesLancet1997350907012410.1016/S0140-6736(97)01107-0

5 

PH Singh AU Surana AN Shah Retinopathy of prematurity in neonatal care unit Int J Contemp Pediatr2016312349

6 

Preterm birth [Internet]. [cited 2019 Nov 23]https://www.who.int/news-room/fact-sheets/detail/preterm-birth

7 

Low birthweight [Internet]. UNICEF DATA [cited 2019 Nov 23]https://data.unicef.org/topic/nutrition/low-birthweight/

8 

R Charan M R Dogra A Gupta A Narang The incidence of retinopathy of prematurity in a neonatal care unitIndian J Ophthalmol19954331236

9 

S Rekha RR Battu Retinopathy of prematurity: incidence and risk factorsIndian Pediatr199633129991003

10 

S Chaudhari V Patwardhan U Vaidya S Kadam A Kamat Retinopathy of prematurity in a tertiary care center--incidence, risk factors and outcomeIndian Pediatr200946321924

11 

Incidence and Risk factors for Retinopathy of Prematurity in Neonates of weight <1.5 kg and/ or <32 weeks of Gestation in a tertiary care HospitalInt J Curr Res Med Sci2019377582

12 

D S P Shetty D J Shetty D H Amin D R D Shenoy The Incidence , Risk Factors and Outcome of Retinopathy of Prematurity at a Tertiary Care Centre in South India2015

13 

A Mantri M Makwana V Goyal V Payal H Mourya P Sharma A prospective study to determine the incidence of retinopathy of prematurity at a tertiary care centre in Western Rajasthan and delineate its risk factorsInt J Contemp Pediatr20194411937

14 

C Le LB Basani D Zurakowski RS Ayyala SG Agraharam Retinopathy of prematurity: Incidence, prevalence, risk factors, and outcomes at a tertiary care center in Telangana J Clin Ophthalmol Res2017431192210.4103/2320-3897.190785

15 

A Parekh M Behera S Kulkarni P Narwadkar S Natu Retinopathy of prematurity: a study of incidence and risk factorsInt J Contemp Pediatr20163413205

16 

A Dwivedi D Dwivedi S Lakhtakia C Chalisgaonkar S Jain risk factors and pattern of severe retinopathy of prematurity in eastern Madhya PradeshIndian J Ophthalmol20196768192310.4103/ijo.IJO_1789_18

17 

T Wu L Zhang Y Tong Y Qu B Xia D Mu Retinopathy of Prematurity Among Very Low-Birth-Weight Infants in China: Incidence and Perinatal Risk FactorsInvest Ophthalmol Vis Sci201859275763

18 

VA Shah CL Yeo YLF Ling LY Ho Incidence risk factors of retinopathy of prematurity among very low birth weight infants in SingaporeAnn Acad Med Singap200534216978

19 

R Karkhaneh S Z Mousavi M Riazi-Esfahani S A Ebrahimzadeh R Roohipoor M Kadivar Incidence and risk factors of retinopathy of prematurity in a tertiary eye hospital in TehranBr J Ophthalmol2008921114469

20 

AHAA Hakeem GB Mohamed MF Othman Retinopathy of Prematurity: A Study of Prevalence and Risk FactorsMiddle East Afr J Ophthalmol20121932899410.4103/0974-9233.97927

21 

ZS Reyes SW Al-Mulaabed F Bataclan C Montemayor A Ganesh S Al-Zuhaibi Retinopathy of prematurity: Revisiting incidence and risk factors from Oman compared to other countriesOman J Ophthalmol2017101263210.4103/ojo.OJO_234_2014

22 

O Onyango S Sitati L Amolo F Murila S Wariua G Nyamu Retinopathy of prematurity in Kenya: prevalence and risk factors in a hospital with advanced neonatal carePan Afr Med J201829115210.11604/pamj.2018.29.152.14046

23 

A Hellström LEH Smith O Dammann Retinopathy of prematurityLancet19913378733834

24 

ZH Wang YY Li ZM Liu Birth weight and gestational age on retinopathy of prematurity in discordant twins in ChinaInt J Ophthalmol201474663710.3980/j.issn.2222-3959.2014.04.14

25 

DB Schaffer EA Palmer DF Plotsky HS Metz JT Flynn B Tung Prognostic factors in the natural course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative GroupOphthalmology199310022307

26 

D Austeng KBM Källen UW Ewald PG Jakobsson GE Holmström Incidence of retinopathy of prematurity in infants born before 27 weeks' gestation in SwedenArch Ophthalmol1960127101315910.1001/archophthalmol.2009.244

27 

WL Li L He XH Liu YM Wang JQ Liu Analysis of risk factors for retinopathy of prematurityInt J Ophthalmol201146631310.3980/j.issn.2222-3959.2011.06.11

28 

M P Chattopadhyay A Pradhan R Singh S Datta Incidence and risk factors for retinopathy of prematurity in neonatesIndian Pediatr2015522157165

29 

AA Ahuja YCV Reddy OO Adenuga D Kewlani M Ravindran R Ramakrishnan Risk factors for retinopathy of prematurity in a district in South India: A prospective cohort studyOman J Ophthalmol201811133710.4103/ojo.OJO_97_2016

30 

AM Freitas R Mörschbächer MR Thorell EL Rhoden Incidence and risk factors for retinopathy of prematurity: A retrospective cohort studyInt J Retina Vitreous2018412010.1186/s40942-018-0125-z

31 

M Khorshidifar H Nikkhah A Ramezani M Entezari N Daftarian H Norouzi Incidence and risk factors of retinopathy of prematurity and utility of the national screening criteria in a tertiary center in IranInt J Ophthalmol201912813306

32 

JBF Filho GU Eckert FB Valiatti MC da Costa PP Bonomo RS Procianoy Prevalence of retinopathy of prematurity: an institutional cross-sectional study of preterm infants in BrazilRev Panam Salud Publica20092632162010.1590/s1020-49892009000900005

33 

IM Omer HA Hassan The prevalence and risk factors of retinopathy of prematurity among preterm babies admitted to Soba Neonatal Intensive Care UnitSudan J Paediatr20141421721

34 

LEH Smith Pathogenesis of retinopathy of prematurityGrowth Horm IGF Res200414Suppl AS140410.1016/j.ghir.2004.03.030

35 

EA Palmer RJ Hardy V Dobson DL Phelps GE Quinn CG Summers 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurityArch Ophthalmol196012333118 10.1001/archopht.123.3.311

36 

Y Alizadeh M Zarkesh RS Moghadam B Esfandiarpour H Behboudi MM Karambin Incidence and Risk Factors for Retinopathy of Prematurity in North of IranJ Ophthalmic Vis Res20151044248

37 

N Ashton B Ward G Serpell Effect of Oxygen on Developing Retinal Vessels with Particular Reference to the Problem of Retrolental FibroplasiaBr J Ophthalmol1954387397432

38 

P Kumar MJ Sankar A Deorari R Azad P Chandra R Agarwal Risk Factors for Severe Retinopathy of Prematurity in Preterm Low Birth Weight NeonatesIndian J Pediatr20117878126

39 

R Saeidi A Hashemzadeh S&amp; R Ahmadi Prevalence and Predisposing Factors of Retinopathy of Prematurity in Very Low-birth-weight Infants Discharged from NICUIran J Pediatr20091915963

40 

A Vinekar M R Dogra T Sangtam A Narang A Gupta Retinopathy of prematurity in Asian Indian babies weighing greater than 1250 grams at birth: Ten year data from a tertiary care center in a developing countryIndian J Ophthalmol20075553316

41 

JW Chang Risk factor analysis for the development and progression of retinopathy of prematurityPLoS One2019147e021993410.1371/journal.pone.0219934

42 

J Alajbegovic-Halimic D Zvizdic E Alimanovic-Halilovic I Dodik S Duvnjak Risk Factors for Retinopathy of Prematurity in Premature Born ChildrenMed Arch20156964091310.5455/medarh.2015.69.409-413

43 

JS Penn MM Henry PT Wall BL Tolman The range of PaO2 variation determines the severity of oxygen-induced retinopathy in newborn ratsInvest Ophthalmol Vis Sci19953610206370

44 

J S Penn M M Henry P T Wall B L Tolman The range of PaO2 variation determines the severity of oxygen-induced retinopathy in newborn ratsInvest Ophthalmol Vis Sci19953610206370



jats-html.xsl

© 2022 Published by Innovative Publication Creative Commons Attribution 4.0 International License (creativecommons.org)